SPANX family member DGenealiases: CT11.4 · SPANX-D · SPANX-E · SPANXE · dJ171K16.1
Q-omics provides the consensus-scored SPANXD profile across patient tissues and cancer cell-line models. SPANXD expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SPANXD is differentially expressed in 2, with the highest sampling consensus in HNSC. Additionally, SPANXD RNA expression shows 7,416 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where SPANXD shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SPANXD — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SPANXD survival associations across molecular data types. SPANXD RNA expression shows survival associations in the most cancer types (17), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SPANXD RNA expression–survival associations across cancer types. High SPANXD expression shows unfavorable associations in KIRC, KICH, UVM, COAD, BLCA and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SPANXD RNA expression.
This table summarizes SPANXD tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SPANXD. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SPANXD shows higher tumor expression in HNSC and LUSC. The HNSC box plot shows higher SPANXD RNA expression in tumor versus normal tissue (log2 FC = +0.453, t-test p = .015).
This table shows molecular features associated with SPANXD in patient tissues and cancer cell lines. In patient samples, SPANXD shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SPANXD RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE.
